




Tumor Board Tuesday and Awareness of Novel Therapies and Toxicities in Solid Tumor Oncology

Johnathan Ebben, MD, PhD^{1,2}; Alison Rothbaum²; Rachel Riechelmann, MD, PhD³; Jéssica Zanotti, MD³; Michael Pishvaian, MD, PhD^{2,4}

¹ University of Wisconsin-Madison Carbone Cancer Center, Madison, WI; ² Tumor Board Tuesday; ³ AC Camargo, São Paulo, Sao Paulo, Brazil; ⁴ Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD



Abstract ID 11008

Follow us

@TumorBoardTues

#TumorBoardTuesday

Take
messages

✓ Tumor Board Tuesday (TBT) engages a **global audience** of academic/community oncologists, trainees, patients and patient advocates, accelerating implementation of practice changes
82% of participants became aware of a new therapeutic option, leading 75% of participants to change a treatment plan based on TBT participation

Anatomy of TBT

- TBT is an oncology learning platform that includes both synchronous and asynchronous elements
- Weekly discussions are led by a topic expert, with a scheduled time of community discussion
- A wrap up summarizes key points and discussion, offering an easy reference to participants

Asynchronous

Monday: Case Introduction


Tuesday: 8 PM EST discussion led by topic specific experts

Thursday: Case summary including video interview with presenters, graphical abstract

Synchronous

The TBT model incorporates both synchronous and asynchronous learning, as well as multimedia components that include video and discussion threads.

- While cases center on specific topics, discussions organically diverge to cover many related areas



TBT by the Numbers

43 cases presented in 2022

Breast (18); Lung (14); GU (11)

6.216M

Impressions

1,961

Tweets

132

Participants

3

Avg Tweets/Hour

15

Avg Tweets/Participant


Tweet

Twitter data from the #TumorBoardTuesday hashtag from Thu, April 13th 2023, 11:20AM to Sat, May 13th 2023, 11:20AM (America/New_York) – Symplur.




The Impact of TBT

Have you become aware of a new treatment strategy through TBT?



Have you/would you change your treatment plan based on a TBT discussion?



76.3% of participants became aware of a new toxicity and/or a new clinical trial that could be an option.

Conclusions

Evaluation of TBT viewership metrics and CME/voluntary poll responses, reveals that the TBT platform is used by a wide variety of academic and community oncologists, as well as patients and patient advocates, and serves as a valuable tool for disseminating and discussing practice-changing advances and building collaborations.

Acknowledgements


TBT is immensely grateful to the patients, advocates, discussants and participants that have shaped TBT into a community. We extend our thanks to Integrity Continuing Education for their administrative assistance.

Some TBT sessions are supported by educational grants from AstraZeneca Pharmaceuticals, Daiichi Sankyo Inc, Exelixis, Janssen Biotech Inc., Merck Sharp and Dohme Corp, and Regeneron Pharmaceuticals and Sanofi.

More Info



Who Participates in TBT?




An optional survey incorporating questions and free response options was made available to the TBT Community (reached via email, Twitter) between 1/15/2023- 2/14/2023; n=38. Word cloud generated from free form response to how TBT has influenced practice.



Tumor Board Tuesday and Awareness of Novel Therapies and Toxicities in Solid Tumor Oncology

Johnathan Ebben, MD, PhD^{1,2}; Alison Rothbaum²; Rachel Riechelmann, MD, PhD³; Jéssica Zanotti, MD³; Michael Pishvaian, MD, PhD^{2,4}

¹ University of Wisconsin-Madison Carbone Cancer Center, Madison, WI; ² Tumor Board Tuesday; ³ AC Camargo, São Paulo, Sao Paulo, Brazil; ⁴ Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD



Abstract ID 11008

Follow us

@TumorBoardTues

Anatomy of TBT

Asynchronous


Monday: Case Introduction

Tuesday: 8 PM EST discussion led by topic specific experts, knowledge assessments (pre and post discussion)


Thursday: Case summary including video interview with presenters, graphical abstract

Synchronous

Participant Demographics



Cross Disease Molecular Comparisons




Original Topic Introduced



Poll for 2nd Line Tx Choice



Molecular Details



Educational "Mini-Tweetorial"




Thursdays Wrap Up Includes a Video



CME Polls





Divergent Discussion Presented NEW Tx Option FOLFIRINOX for NE Cancer



Promising trials, and trial designs discussed

Who Participates in TBT?



6.216M Impressions

1,961 Tweets

132 Participants

3 Avg Tweets/Hour


15 Avg Tweets/Participant

Tweet


Twitter data from the [#TumorBoardTuesday](#) hashtag from Thu, April 13th 2023, 11:20AM to Sat, May 13th 2023, 11:20AM (America/New_York) – Symplur.



Have you become aware of a new treatment strategy through TBT?



Have you/would you change your treatment plan based on a TBT discussion?



76.3% of participants became aware of a new toxicity and/or a new clinical trial that could be an option.

The TBT platform is accessed and used by oncologists, patients, and patient advocates across practice types, including beyond the United States.

TBT is a valuable tool for disseminating practice changing information and building an online community to advance oncology care.